Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.

Journal of veterinary internal medicine - 1 Jan 2018

Weishaar K M, Ehrhart E J, Avery A C, Charles J B, Elmslie R E, Vail D M, London C A, Clifford C A, Eickhoff J C, Thamm D H

Abstract excerpt

BACKGROUND: KIT inhibitors, such as toceranib (TOC), and vinblastine (VBL) have not been prospectively compared in the treatment of macroscopic mast cell tumors (MCTs). Also, it is unknown whether VBL or TOC is superior for treating MCT without c-kit mutations. HYPOTHESIS/OBJECTIVES: To determine the value of KIT genotyping and localization in treatment decisions for dogs with macroscopic MCT. We hypothesized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Dog Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Prednisone

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Vinblastine

Source

Open in PubMed Open full text

Identifiers

PMID: 29194765
DOI: 10.1111/jvim.14889
PMCID: PMC5787208

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.PMID 29194765Read ↗

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatmentSemantic proximity Read ↗

Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline.Semantic proximity Read ↗

The Role of c-KIT in Tumorigenesis: Evaluation in Canine Cutaneous Mast Cell TumorsSemantic proximity Read ↗

c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.Semantic proximity Read ↗

Internal Tandem Duplication of Exon 8 of c-kit Is Associated With Longer Total Survival in Canine Cutaneous Mast Cell Tumors.Semantic proximity Read ↗

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.Semantic proximity Read ↗

A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.Semantic proximity Read ↗

Cutaneous MCTs: Associations with Spay/Neuter Status, Breed, Body Size, and Phylogenetic ClusterSemantic proximity Read ↗

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.Semantic proximity Read ↗

Canine Mast Cell Tumors: Correlation of Apoptosis and Proliferation Markers with PrognosisSemantic proximity Read ↗

A case report of feline mast cell tumour with intertumoral heterogeneity: Identification of secondary mutations c.998G>C and c.2383G>C in KIT after resistance to toceranib.Semantic proximity Read ↗

Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.